ADVENT-HF Trial Shows Promise for Peak Flow-Triggered ASV in Heart Failure Patients with Sleep Apnea
• The ADVENT-HF trial demonstrated that peak flow-triggered adaptive servo-ventilation (ASV) devices improved sleep quality and quality of life in heart failure patients.
• Unlike the SERVE-HF trial, ADVENT-HF did not find an increased risk of mortality with ASV use; mortality trended lower, though not statistically significant.
• The study highlights that ASV devices are not generic, with efficacy and safety varying based on manufacturer-specific algorithms and triggering mechanisms.
• ADVENT-HF used Philips Respironics BiPAP autoSV Advanced, which differs from the minute ventilation-triggered ASV used in SERVE-HF, potentially explaining the divergent outcomes.
© Copyright 2025. All Rights Reserved by MedPath